CMND | Clearmind Medicine Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.3300 - 1.3550
52 Week Range	0.9210 - 6.80
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	16,403
Average Volume	265,910
Shares Outstanding	4,056,335
Market Cap	5,394,926
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-11-15

Valuation
Profitability
Growth
Health
P/E Ratio	-1.08
Forward P/E Ratio	N/A
EPS	-1.23
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	Canada
Website	CMND

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

CMND's peers: TLSA, OKYO, HILS, COEP, MGTA, QNRX, CDIO, WINT, NBY, BXRX, REVB, BWV, PXMD, UNCY, VRAX, IMMX, CNSP, EFTR, NAVB, SONN

*Chart delayed

Analyzing fundamentals for CMND we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see CMND Fundamentals page.

Watching at CMND technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CMND Technicals page.